CRISPR Therapeutics AG Stock News

CRISPR Therapeutics AG (NASDAQ:CRSP ) William Blair's 45th Annual Growth Stock Conference June 3, 2025 12:20 PM ET Company Participants Raju Prasad - Chief Financial Officer Conference Call Participants Sami Corwin - William Blair Sami Corwin Hi, everyone. We're going to get started.

Are you just as afraid of a market pullback right now as you are of missing out on upside? If so, you're not alone.

Even though broader equities have been highly volatile this year, it's still a good idea to invest in stocks for a straightforward reason. Holding shares of top companies for five years and beyond will usually allow anyone to earn superior returns.

ZUG, Switzerland and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in June. William Blair's 45 th Annual Growth Stock Conference Date:...

The professionals who manage Wall Street funds and cater to wealthy investors live and die by their quarterly performance. However, the individual investor can win the long game by focusing on what will matter the most years into the future.

Shares of gene therapy specialist, CRISPR Therapeutics (CRSP -0.34%) have been beaten down a long way despite some impressive accomplishments. The company already earned approval to sell its first treatment from the Food and Drug Administration (FDA), but the stock price is way down.

Despite making significant clinical progress, CRISPR Therapeutics (CRSP 6.83%) has been struggling financially in the past three years. The company's shares are down by 24% over this period, while the S&P 500 has gained 41%.

Ever since scientists began mapping the human genome, gene editing has always been the end goal. The idea once seemed like something out of a science fiction novel, but it's here today and CRSPR Therapeutics AG NASDAQ: CRSP is leading the way.